

## Forkhead Homeobox Type O Transcription Factors in the Responses to Oxidative Stress

Peter Storz

### Abstract

Reactive oxygen species (ROS) and cellular oxidative stress are involved in many physiological and pathophysiological processes, including cellular and organismal aging, migration, proliferation, senescence or death of normal and cancer cells, and stress resistance of stem cells. The forkhead homeobox type O (FOXO) transcription factors FOXO1, FOXO3a, and FOXO4 are critical mediators of the cellular responses to oxidative stress and have been implicated in many of the above ROS-regulated processes. In cancer cells they converge oxidative stress signaling to cell cycle arrest and cell death or promote a motile phenotype. Dependent on their posttranslational modifications FOXOs can also actively regulate the detoxification of cells from ROS and promote stress resistance. Thus, FOXO transcription factors are of vital importance in processes regulating tumor survival or progression, stem cell maintenance, age-related pathological processes, and lifespan extension. *Antioxid. Redox Signal.* 14, 593–605.

### Introduction

#### *Generation of cellular oxidative stress*


REACTIVE OXYGEN SPECIES (ROS) are normal byproducts of cellular functions or are specifically generated to facilitate intracellular signaling (Fig. 1). They can be divided into nonradical ROS such as hydrogen peroxide ( $H_2O_2$ ), and free oxygen radicals such as superoxide ( $O_2^{\bullet-}$ ) or hydroxyl radicals ( $\bullet OH$ ) [reviewed in (75)]. Major sources for intracellular ROS are mitochondria, which generate  $O_2^{\bullet-}$  and  $H_2O_2$  as byproducts of cellular energy production (112). Other inducers of ROS to facilitate signaling are growth factors and cytokines such as insulin, transforming growth factor  $\beta$ , or tumor necrosis factor  $\alpha$ , which all increase  $O_2^{\bullet-}$  generation through activation of NADPH oxidases or *via* the mitochondria (75). Oxidative stress conditions occur within cells when cellular detoxification by antioxidants is decreased, when oxygen radicals are increasingly generated, or cells are exposed to an extracellular source of ROS (31). This may occur in cells through mitochondrial dysfunction, increased metabolic activity, starvation, altered glucose levels, oncogenic activity, increased cellular receptor signaling, decreased antioxidant capacity, or through crosstalk with immune cells (Fig. 2) (4, 110, 115). ROS are not hazardous by virtue, since they are important mediators of multiple cellular processes, including cell proliferation, survival, and migration. However, an accumulation of ROS within cells leading to oxidative stress can tip the balance from oncogenic to quiescent or apoptotic signaling. Such various responses leading to tumor

promotion or inhibition [reviewed in (75, 110)] or a senescent phenotype [reviewed in (36, 77)] are dependent on the cell or tissue type, the radical formed and its concentration, as well as the location where these ROS are generated.

#### *Regulation of cellular oxidative stress*

Intracellular ROS homeostasis is steadily maintained by cellular detoxification systems to prevent cells from damage. Detoxification of cells from oxidative stress is mediated through antioxidant enzymes that specifically scavenge different kinds of ROS and by nonenzymatic molecules (Fig. 3) [reviewed in (75)]. The dismutation of  $O_2^{\bullet-}$  anions to oxygen and  $H_2O_2$  is mainly mediated by superoxide dismutases (SODs). SOD enzymes are located in different compartments within the cell, such as MnSOD in the mitochondrial matrix and Cu/ZnSOD in the cytosol (25).

Decomposition of  $H_2O_2$  to water and oxygen is mediated by various enzymes such as catalase, located at the cytosol (8, 45, 76) and several peroxiredoxins (Prxs) located at peroxisomes, mitochondria, and the cytosol (46, 101, 133). Further, glutathione (GSH) peroxidases, localized in cytosol and mitochondria, catalyze the breakdown of  $H_2O_2$  and organic hydroperoxides (13, 124). Thioredoxins (Trx) act as electron donors to peroxidases and also facilitate the reduction of proteins by cysteine thiol disulfide exchange (3). Nonenzymatic molecules that detoxify cells from ROS are for example vitamins A, C, and E, and GSH. GSH protects cells from oxidative stress by reducing disulfide bonds of cytoplasmic




**FIG. 1. Reactive oxygen species (ROS) and their roles within cells.** Major ROS in cells include superoxide ( $O_2^{\bullet-}$ ), hydrogen peroxide ( $H_2O_2$ ), and hydroxyl ions ( $\bullet OH$ ).  $O_2^{\bullet-}$  is mainly generated by mitochondria or NADPH oxidase enzymes and induces cell proliferation and motility.  $O_2^{\bullet-}$  is dismutated to  $H_2O_2$  whose major role is in inducing apoptotic or necrotic cell death. Both  $O_2^{\bullet-}$  and  $H_2O_2$  can form macromolecule damaging hydroxyl ions that can contribute to senescence and cell death.


proteins to cysteines. During this process, GSH is oxidized to GSH disulfide. The regeneration of GSH pools is mediated by GSH reductase, an enzyme that reduces GSH disulfide (10, 22).

#### Cellular sensing of oxidative stress

Within recent years it became apparent that ROS-sensing signaling molecules exist that are activated at the location of ROS generation and translate increased oxidative stress into induction of protective or apoptotic signaling pathways



**FIG. 2. Inducers of oxidative stress.** Oxidative stress occurs when the cells' antioxidant capacity is reduced or exceeded. Inducers of cellular oxidative stress are increased metabolic activity, mitochondrial dysfunction, decreased antioxidant capacity, starvation and nutrient restriction, altered glucose levels, oncogenic signaling, increased growth factor or cytokine signaling, or the crosstalk of cells with immune cells.



**FIG. 3. Detoxification of cellular ROS.** The detoxification of cells from ROS is mediated by various antioxidant proteins and small molecules. Superoxide dismutase (SOD) enzymes convert  $O_2^{\bullet-}$  to  $H_2O_2$ .  $H_2O_2$  is further hydrolyzed to water *via* catalase, the glutathione/glutathione peroxidase system, or the thioredoxin/peroxiredoxin system.


[discussed in (112)]. Such cellular ROS sensors can be activated by direct oxidation through  $O_2^{\bullet-}$  or  $H_2O_2$ .  $O_2^{\bullet-}$  regulates the activity of proteins that contain iron sulfur centers (37).  $H_2O_2$  reversibly oxidizes the sulfhydryl group in the active site cysteine residues of several phosphatases, and similar regulation was shown for kinases and transcription factors (84, 91, 117, 134). Whereas the importance of oxidative stress in inducing necrosis and apoptosis is focus of intensive investigation, only little is known about ROS-sensing signaling molecules that mediate cell survival or protection from ROS under moderate levels of oxidative stress through induction of antioxidant nuclear genes. One example, for ROS-induced protective signaling is an Src-initiated signaling pathway that promotes cancer cell survival through activation of NF- $\kappa$ B (112), and Src has a cystein residue motif that allows activation of the kinase through direct oxidation (91). Forkhead homeobox type O (FOXO) transcription factors can also be viewed as sensors for oxidative stress since their activity is regulated by  $H_2O_2$  and dependent on the cellular context they relay these stresses to induce apoptosis, stress resistance, or senescence (17, 34). Recently, it was reported that FOXO4 can be directly regulated by the cellular redox state through either monoubiquitination (126) or the induction of cysteine-thiol disulfide-dependent complexes of FOXO with the acetyltransferase p300/cAMP-response element binding protein (CREB)-binding protein (CBP) (27). Binding of p300/CBP to FOXO is essential for FOXO-mediated transcription, since both CBP and p300 act as FOXO cofactors by weakening histone/DNA interactions (125). The modulation of FOXO biological activity by p300/CBP-mediated acetylation is completely dependent on the formation of the redox-regulated complexes, suggesting that FOXO transcription factors are *bona fide* sensors for the redox status of cells. The modulation of such ROS-sensing signaling molecules and the development of inhibitors or mimetics may reveal strategies to extend lifespan in humans or to prevent ROS-caused diseases.

#### Oxidative stress in aging and age-related diseases

A cellular shift toward oxidative stress conditions can lead to macromolecule damage such as lipid peroxidation, protein oxidation and aggregation, or DNA modification. Over time, ROS-mediated damage is accumulated and this may facilitate aging processes within cells and overall in the organism as it was formulated in the free radical theory of aging (Fig. 4) (44).

**FIG. 4. The balance between antioxidant capacity and ROS.**

ROS have important functions in normal cell behavior, but also in disease. Thus, high and very low levels of ROS within cells lead to impaired cellular functions. However, ROS levels at which cells perform normal physiological functions can lead to the damage of macromolecules. Accumulation of damaged macromolecules over time leads to cellular and organismal aging. Increased generation of ROS or decreased antioxidant capacity promotes aging and age-related disease. On the other hand, decreased oxidative stress or increased antioxidant capacity promote longevity. ROS sensor systems detect changes in intracellular oxidative stress and promote cell death or protection/detoxification. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at [www.liebertonline.com/ars](http://www.liebertonline.com/ars)).



This hypothesis is supported by the observation that the lifespan of a wide spectrum of animals is proportional to their metabolic rate and therefore to the rate at which the organisms generate ROS [summarized in (111)]. Dietary and chemical antioxidants as well as caloric restriction can lower cellular ROS production and this translates to an extension of lifespan [summarized in (36)]. Consequently, increased life span correlates with increased stress resistance and expression of nuclear stress response genes encoding antioxidant and stress-regulating proteins. Increases in intracellular oxidants are believed to be responsible for the onset and progression of >40 human diseases, including ischemic heart disease, neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease, diabetes, and cancer [summarized in (35, 105)]. Therefore, aging as well as the development of age-related disease are dependent on the rates of ROS generation or detoxification, whereby ROS levels are impacted by dietary and cellular antioxidants as well as the ability of cells to replace oxidative-damaged macromolecules over time (66).


### FOXO Transcription Factors in the Responses to Oxidative Stress

#### Regulation of FOXO transcription factor activity by oxidative stress

FOXO transcription factors are regulated by a multitude of kinases of which some mediate activating and others inhibiting phosphorylations (in detail reviewed by Van den Berg *et al.* in this issue). An increase in intracellular ROS facilitates the localization of FOXO to the nucleus where it is transcriptionally active (34). Mimicking such oxidative stress conditions by treating cells with  $H_2O_2$  revealed that in response to ROS, c-Jun-N-terminal kinase (JNK) is a major inducer of FOXO activity. However, additional posttranslational modifications are needed to exert the full spectrum of FOXO-mediated responses to ROS (Fig. 5) [reviewed in (126)].

#### Activation of FOXO transcription factors through ROS-regulated kinases

Particularly two kinases, JNK and mammalian ortholog of the Ste20-like protein kinase (MST-1), have been implicated in  $H_2O_2$ -mediated activating phosphorylations of FOXOs. Upon treatment with  $H_2O_2$  or after activation of the small GTPase Ral, JNK interacts with FOXO and phosphorylates FOXO directly at two threonine residues (Thr447 and Thr451 in FOXO4), leading to its nuclear translocation and activation (34, 64). JNK previously has been described to be activated by



**FIG. 5. Activation of forkhead homeobox type O (FOXO) through ROS-induced posttranslational modifications.** An increase in intracellular reactive ROS induces the activation of the kinase c-Jun-N-terminal kinase (JNK) and the acetylating enzyme complex p300/cAMP-response element binding protein (CREB)-binding protein. Phosphorylation, acetylation, and monoubiquitination status of FOXO can lead to the induction of a specific subset of genes that regulate cellular detoxification, cell cycle arrest, and DNA repair or apoptosis.

mitochondrially produced  $H_2O_2$ . Once activated at these organelles in cancer cells JNK induces apoptosis by negative regulation of Bcl-2 function and activation of Bax [summarized in (112)]. Other functions of ROS-JNK-FOXO signaling is a contribution to insulin resistance (32) and to an increased lifespan in worm, fly, and rodents (97, 131).

Like JNK, MST-1 is a kinase involved in ROS-induced signaling. MST-1 mediates oxidative stress-induced and growth factor withdrawal-induced neuronal apoptosis through phosphorylation and activation of FOXO (*i.e.*, phosphorylation of FOXO3a at S207) (139). This phosphorylation induces nuclear accumulation of FOXO by disrupting its association with 14-3-3 proteins (55, 70). MST-1 is also a physiological substrate for Akt and phosphorylation of MST-1 at Thr 387 by Akt blocks the activation of FOXO3a by this kinase (55).

#### *Role of ROS in signaling pathways that negatively regulate FOXO*

FOXO transcription factors are negatively regulated by insulin/insulin-like growth factor-1 (IGF-1) signaling pathways, mainly by PI3K-mediated activation of the kinases serum- and glucocorticoid-inducible kinase (SGK) (16) and Akt (14). Phosphorylation of FOXO by Akt or SGK leads to binding of 14-3-3 proteins and subsequent nuclear export (15). Other negative regulators of FOXO-mediated gene induction are inhibitor of nuclear factor- $\kappa$ B kinase (IKK) and Pin1. All these proteins have been shown to be activated by oxidative stress (14, 53), adding an additional level of complexity to the regulation of FOXO. Pin1, for example, in response to oxidative stress interacts with FOXO4 and attenuates its monoubiquitination to inhibit transcriptional activity (12). Dependent on the cellular context, oxidative stress can increase Akt activity. However, in some cell systems, it was shown that oxidative stress actually downregulates IGF-1-mediated Akt signaling. Others have shown that oxidative stress allows FOXO to accumulate in the nuclei of cells in response to stresses though active growth factor signaling and the presence of Akt/SGK-mediated phosphorylations (17, 38, 62). Moreover, increases in oxidative stress under conditions where Akt is inactive lead to increased activity of FOXO transcription factors. This may occur in starved cancer cells in which starvation-mediated increase in cellular oxidative stress leads to the activation of FOXO3a (113). Other examples are quiescent cells in which FOXO3a activity is increased by  $H_2O_2$ -induced oxidative stress (64).

#### *Regulation of FOXO by nutrients and dietary restriction*

Glucose and glucose metabolism can induce oxidative stress and activate JNK, suggesting a ROS-JNK-mediated regulation of FOXO at high glucose levels. Additionally, O-linked beta-N-acetylglucosamine modification regulates FOXO1 in response to glucose and results in increased expression of gluconeogenic and of ROS detoxifying genes. This provides a mechanism for direct nutrient control of transcription to regulate metabolism and stress response through FOXOs (51). Overall, FOXO activity induces a metabolic switch that is similar to low glucose and fasting conditions. This is mediated by FOXO-induced suppression of genes involved in glycolysis and lipogenesis (140) and expression of genes essential for the regulation of gluconeogenesis (7, 90).

Dietary restriction is the most potent intervention to slow aging in a variety of species (132). Possible mediators of caloric restriction are the sirtuins, which possess nicotinamide adenine dinucleotide-dependent protein deacetylase activities (54). SIRT1 protein levels are upregulated by caloric restriction or fasting (24, 103) and deacetylate histones and multiple transcription factors such as p53, NF- $\kappa$ B, and FOXO (17, 78, 88, 127, 136). For example, upon peroxide stress deacetylation by SIRT1 prolongs FOXO4-dependent transcription of stress-regulating genes (127). Similarly, SIRT1 increases FOXO3a's ability to induce cell cycle arrest and resistance to oxidative stress but inhibited its signaling to induce cell death (17). The SIRT1 homolog SIRT2 deacetylates  $\alpha$ -tubulin, but also enters the nucleus and deacetylates histones and FOXO transcription factors (shown for FOXO3a) in response to both oxidative stress (as induced by  $H_2O_2$ ) and caloric restriction (130). After its induction by oxidative stress, SIRT2 activity induces cytostatic, pro-apoptotic, or antioxidant factors such as p27<sup>kip1</sup>, Bcl-2-interacting mediator of cell death (Bim), and MnSOD probably through its effects on FOXO.

#### **Targets for FOXO in Response to Oxidative Stress**


The activation of FOXO transcription factors due to absence of insulin/IGF-1 signaling or increased oxidative stress can induce a wide range of genes that regulate cellular responses such as cell cycle arrest and apoptosis or stress responses, including resistance to oxidative stress (Fig. 6). These various functions can be mediated by posttranslational modifications and/or different FOXO interaction partners that modulate FOXO targeting [reviewed in (21)].

#### *FOXO targets genes involved in cellular detoxification of ROS*

Management of intracellular ROS to prevent macromolecule damage is achieved through cellular enzymes or small molecules that collectively form the cellular antioxidant system (49). Important ROS within cells are  $O_2^{\bullet-}$ ,  $H_2O_2$ , or the DNA-damaging hydroxyl ions (111). One role of FOXO in the stress response is the upregulation of antioxidant proteins that mediate detoxification of ROS and stress resistance that is tightly linked to increased lifespan. Moreover, FOXO-mediated redox regulation has been implicated in tumor suppression (21). The activation of FOXO transcription factors leads to the induction of a variety of genes encoding antioxidant proteins, including MnSOD, which detoxifies cells from mitochondrially generated  $O_2^{\bullet-}$  (64). In *Caenorhabditis elegans* mRNA levels of MnSOD are negatively regulated by the insulin/IGF-1 signaling pathways (48). The exposure of quiescent cells to  $H_2O_2$  activates FOXO3a, leading to expression of MnSOD *via* regulation of the *SOD2* gene (64). However, it was also shown that in tumor cells under normal growth conditions FOXO transcription factors may be dispensable from mROS-mediated induction of *SOD2* (114).

$H_2O_2$  is hydrolyzed by a variety of antioxidant proteins of which several are also regulated in their expression by FOXO, indicating that activation of FOXO can indeed lead to a complete detoxification of ROS. For example, the forkhead-type transcription factor DAF-16 in nematodes induces expression of catalase after its activation by hyperosmotic stress, high fever stress, oxidative stress, and nutrient starvation (52,

**FIG. 6. ROS-FOXO regulation of genes.** Oxidative stress-mediated activation of FOXO was shown to regulate a variety of genes, including genes that promote cell motility, stress resistance, quiescence and self renewal, or cell death. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at [www.liebertonline.com/ars](http://www.liebertonline.com/ars)).



67, 96). In human cells FOXO3a also induces expression of catalase (40, 93). Moreover, the JNK-FOXO signaling pathway upregulates expression of Prx II a protein that is mainly expressed in the adult brain (69). Another FOXO target in human cardiac fibroblasts is the gene promoter of the mitochondria-located Prx III (23). Depletion of Prx III in cardiac fibroblasts was associated with decreased resistance to oxidative stress (23). This is important since after myocardial injury, human cardiac fibroblasts are protected from oxidative stress (72) by expressing FOXO-regulated antioxidant molecules such as SODs, catalases, and Prxs.

Selenoprotein P, the major selenoprotein in human plasma, can act as an antioxidant and its expression in hepatoma cells is regulated at the promoter level through the interaction of FOXO1, peroxisomal proliferator-activated receptor- $\gamma$  coactivator 1 $\alpha$ , and hepatocyte nuclear factor-4 $\alpha$  (108, 129). Moreover, the *sestrin 3* gene is a FOXO3a target that acts as a ROS scavenger (94). Sestrins accumulate in cells exposed to oxidative stress and loss of sestrin in *drosophila* results in age-associated pathologies, including mitochondrial dysfunction and cardiac malfunction (68).

FOXO1 also directly represses expression of Trx-interacting protein in human cells. Trx-interacting protein hinders the cellular response to oxidative stress and affects life span (28) by inhibiting the reducing activity of Trx, an antioxidant protein that acts as electron donor to peroxidases and also facilitates the reduction of proteins by cysteine thiol disulfide exchange (3). Additionally, FOXO upregulates the fatty acyl-CoA carriers sterol carrier protein X and sterol carrier protein 2, which both protect unsaturated fatty acids from oxidative damage (26). Finally, FOXO3a directly activates the human MstA promoter in human cells and in *C. elegans*, contributing to maintain the methionine sulfoxide reductase system that protects against oxidative stress and was implicated in the regulation of aging (86).

#### Regulation of ROS-induced cell cycle arrest and apoptosis by FOXO

The mechanisms by which FOXO transcription factors switch from antioxidant signaling to apoptotic signaling are not well defined. FOXO transcription factors integrate stress stim-

uli *via* phosphorylation, acetylation, and mono-ubiquitination events [summarized in (43)], and this as well as alternate binding partners may define the cellular program activated. FOXO functions in ROS signaling may also be dependent of the differentiation state of cells. For example, it was shown that in undifferentiated 3T3-L1 cells FOXO3a mediates ROS-induced apoptosis, whereas in differentiated 3T3-L1 adipocytes FOXO3a suppressed ROS-induced apoptosis *via* a switch to increased expression of ROS scavenging enzymes (63).


The therapeutic potential of FOXO transcription factors in cancer is due to their ability to induce cell cycle arrest and apoptosis [for a review on the therapeutic value of FOXOs see (80)]. In cancer cells, FOXO is activated by anticancer drugs, radioisotope irradiation, or serum starvation, all inducers of intracellular oxidative stress. All these events can cause cell cycle arrest and/or apoptosis through FOXO. In response to oxidative stress FOXO induces expression of genes that regulate DNA repair and cell cycle arrest, including growth arrest- and DNA damage-inducible gene 45 $\alpha$  (GADD45 $\alpha$ ), p130, and cyclin D2 and the cell cycle inhibitors p21 and p27<sup>kip1</sup> (18, 39, 82, 83, 120). For example, in thyroid cancer, FOXO is activated by H<sub>2</sub>O<sub>2</sub> through JNK to induce the genes encoding p27<sup>kip1</sup> and GADD45 $\alpha$  (59). Serum starvation-mediated nuclear localization of FOXO (here FOXO1) was also observed in medulloblastoma cells where it induces growth suppression (109). In *C. elegans* the homolog of human host cell factor-1 binds to DAF-16 and acts as a negative regulator to modulate stress response and longevity (71). In mammals host cell factor-1 is required for appropriate transition from G1 to S phase and progression of M phase and cytokinesis (56, 123), and the binding and inactivation of FOXOs by this factor can be one of the mechanisms of how it exerts its functions (71).

Some anticancer drugs activate apoptosis through FOXO. For example, adriamycin regulates cell death through activation of FOXO1 and tumor necrosis factor receptor-associated death domain (104). Pro-apoptotic targets for FOXO are for example Bim, Bcl-6 (B-cell/lymphoma 6), and the Fas ligand (30). In addition, other signaling proteins such as p66<sup>Shc</sup> and p53 that interact with forkhead transcription factor-mediated pathways have been implicated in the induction of cell cycle arrest and apoptosis in response to ROS

(14, 138). For example, p53 is stabilized by stresses and, once activated, induces expression of cell cycle arrest genes, including p21 (95). In response to DNA damage p53 activation can lead to FOXO3a inhibition (137). Moreover, coexpression of p53 with FOXO3a under oxidative stress conditions leads to decreased expression of the FOXO3a-regulated apoptotic genes *Bim* and *Bcl-6*, but had no effect on *p27* and *CyclinG2* expression (87). Therefore, a crosstalk between FOXO and p53 may be a threshold for apoptotic signaling (87). FOXO and p53 interact in response to cellular stresses that increase ROS levels such as serum deprivation, drug treatment, and treatment of cells with H<sub>2</sub>O<sub>2</sub> (87). However, it is not known if direct interaction is the mechanism of how p53 regulates FOXO3a-mediated transcription.

#### The WNT signaling pathway as a target for ROS-activated FOXO

The WNT (*wingless*) signaling pathway is involved in many physiological and pathophysiological activities and regulates lipid metabolism and glucose homeostasis. A major effector of canonical WNT signaling is a transcription complex formed by free  $\beta$ -catenin and TCF (T cell factor) that drives gene transcription. Overexpression of FOXO led to a reduced binding between TCF and  $\beta$ -catenin and to FOXO/ $\beta$ -catenin complex formation (50). Additionally, oxidative stress as induced by H<sub>2</sub>O<sub>2</sub> strengthened the binding between FOXO and  $\beta$ -catenin (49, 50) and led to enhanced FOXO transcriptional activity (33). FOXO competes with TCF for the same binding site at  $\beta$ -catenin and suppresses  $\beta$ -catenin/TCF signaling toward proliferation, thus attenuating WNT-mediated signaling activities (Fig. 7) (65). This is supported by findings showing that colon carcinoma cells with activated  $\beta$ -catenin/TCF are arrested in their cell cycle in G1 when active FOXO is ectopically expressed (33). The antagonism of WNT signaling by oxidative stress and FOXO could be a common molecu-



**FIG. 7. ROS-activated FOXO as a molecular switch from proliferation to cell cycle arrest.** In WNT signaling the transcription complex of TCF (T cell factor) and  $\beta$ -catenin mediates cell proliferation. H<sub>2</sub>O<sub>2</sub>-mediated activation of FOXO or ectopic expression of FOXO leads to competition of FOXO with TCF for binding to  $\beta$ -catenin. Newly formed FOXO/ $\beta$ -catenin complexes then mediate the induction of cell cycle arrest genes.

lar mechanism that contributes to several pathologies that become more prevalent with increasing age, including insulin resistance, arteriosclerosis, and osteoporosis (81).


#### Functions of FOXO in the Stress Response

Aging is associated with an increased onset of age-related diseases, including neurodegenerative diseases and cancer. However, the molecular mechanisms of how increased age sensitizes organisms to such diseases are not well understood (35, 111). FOXO transcription factors were implicated in regulating aging and multiple age-related diseases (Fig. 8). One potential mechanism of how FOXOs impact these processes is by increasing the antioxidant capacity of cells (48, 57, 64).

#### Role of ROS-FOXO signaling in the regulation of lifespan

Oxidative stress is one of the key factors that limit the lifespan of organisms, since aging as well as age-related diseases can result from the accumulation of damage caused by oxidative stress (44). Consequently, increases in oxidative stress resistance in invertebrates are associated with an increase in their lifespan (74, 85). For example, in *C. elegans* an increase in MnSOD or catalase expression was linked to increased lifespan (48, 98, 99, 116). In *C. elegans* longevity is regulated by the DAF-2 signaling network, which induces the expression of antioxidant defense enzymes such as MnSOD (48). The *daf-2* gene encodes a member of the insulin receptor family and mutations in this gene confer the longevity and the *dauer* stage phenotype, a growth-arrested larval form specialized for dispersal. Similarly to worm, the attenuation or disruption of the insulin/IGF-1 signaling pathways in mice or rats resulted in increased longevity (11, 47, 106).

The adapter protein p66<sup>Shc</sup> of which a fraction of the intracellular pool localizes to the mitochondria accelerates aging (9). Mice with a homozygous deletion p66<sup>Shc</sup> have an extended life span and cells derived from these mice exhibit lower levels of ROS (92). It was suggested that p66<sup>Shc</sup> may impact life span by repartitioning metabolic energy conver-



**FIG. 8. ROS-FOXO pathway as a regulator of aging and age-related diseases.** In response to oxidative stress, FOXO transcription factors were implicated in regulating aging and contributing to multiple age-related diseases. One potential mechanism of how FOXOs impact these processes is by increasing the antioxidant capacity of cells or inducing cell death.

sion away from oxidative and toward glycolytic pathways. Such a metabolic switch was demonstrated with p66<sup>Shc</sup> negative cells that showed a defect in their mitochondrial oxidative capacity and reduced mitochondrial NADH metabolism, but also an increase in lactate production and a stricter requirement for extracellular glucose to maintain intracellular ATP levels. FOXO mediates oxidative stress resistance in p66<sup>Shc</sup> negative cells (93).

In contrast to humans and rodents, which have four functional *foxo* genes (encoding FOXO1, FOXO3a, FOXO4, and FOXO6), *D. melanogaster* and *C. elegans* have only one *foxo* gene encoding dFOXO in fly and DAF-16 in worm, respectively (121). This makes them ideal systems to investigate the role of FOXO transcription factors in aging. In *C. elegans* insulin/IGF-1 signaling decreases stress resistance and longevity by inhibiting the FOXO protein DAF-16 (122). On the other hand, altered expression or regulation of FOXO in both *D. melanogaster* and *C. elegans* resulted in increased longevity (41, 73, 96). The effects on DAF16/FOXO on lifespan have been linked to the antioxidant capacity of FOXO. Additionally, insulin/IGF-1 signaling inhibits SKN-1, a *C. elegans* transcription factor that also has a function in the defense against oxidative stress that mobilizes the conserved phase 2 detoxification response. Like in FOXO, this inhibition is mediated by the insulin effector kinases Akt1/2 and SGK-1, which both phosphorylate SKN-1. However, although SGK-1 and FOXO both contribute to increased stress tolerance and longevity, they are most likely independent downstream targets for the insulin signaling pathway (122).

#### ROS-FOXO signaling in age-related diseases

In AD the accumulation of amyloid beta-peptide (A $\beta$ ) plays a critical role in synapse and neuronal loss. One of the mechanisms by which A $\beta$  is believed to mediate neuronal cell death is through increased oxidative stress. The treatment of primary neuronal cultures with A $\beta$  induced p66<sup>Shc</sup> phosphorylation through JNK and caused apoptotic death (107). A $\beta$  also induced the phosphorylation and inactivation of forkhead transcription factors, overriding the activating effects of JNK on FOXO. On the other hand, ectopic expression of a p66<sup>Shc</sup> mutant that cannot be phosphorylated by JNK or antioxidant treatment protected cells against A $\beta$ -induced death and also reduced FOXO inactivating phosphorylations. This suggests that the redox regulation of forkhead proteins through JNK/Shc signaling underlies A $\beta$  toxicity, a finding that could be potentially useful to develop therapeutic targets for AD.

Loss of bone mass with advancing age or during osteoporosis is associated with decreased canonical WNT signaling correlating with decreased osteoblast numbers (2). WNT is an essential stimulus for osteoblastogenesis and oxidative stress is a pathogenic factor of bone loss in mice, leading to a decrease in osteoblast number and bone formation [reviewed in (81)]. In osteoblasts H<sub>2</sub>O<sub>2</sub> promotes a diversion of the limited pool of  $\beta$ -catenin from TCF- to FOXO-mediated transcription. This leads to an attenuation of osteoblastogenesis, osteoblast differentiation, and bone formation as observed in mice after the age-dependent increase in oxidative stress. However, among the different FOXO transcription factors, FOXO1 was shown to be a positive regulator of bone formation, since it is required for prolifer-

ation, protein synthesis, and resistance to oxidative stress in osteoblasts (2a, 100).

Increased production of ROS was also implicated in the development of age-related cardiovascular diseases. It was shown that moderate overexpression of SIRT1 can protect the heart from oxidative stress. This is due to increased expression of FOXO-regulated genes, including catalase. High levels of SIRT1, however, can also increase basal levels of oxidative stress (1).

Some observations suggest that FOXO1 can promote type II diabetes when constitutively active. Increased FOXO activity contributes to insulin resistance in several animal models for insulin resistance and diet-induced diabetes (89). FOXO factors can act at multiple levels to increase systemic glucose. For example, in hepatocytes sirtuin activation or H<sub>2</sub>O<sub>2</sub> cause nuclear translocation of FOXO1, leading to activation of gluconeogenesis and glycogenolysis (38). Increased glucose concentrations and oxidative stress can also result in JNK-dependent nuclear localization of FOXO1 in pancreatic  $\beta$ -cells, where active FOXO1 reduces the net insulin production through decreasing insulin secretion or attenuating  $\beta$ -cell division [reviewed in (42, 60)]. Pancreatic  $\beta$ -cells are located in the islets of Langerhans and regulate glucose homeostasis through insulin production. FOXO1 expression in islets is increased in diabetic patients (61). Pancreatic  $\beta$ -cell failure is commonly seen in type II diabetes and is caused by chronic exposure of cells to elevated glucose concentrations (glucose toxicity). This glucose toxicity is induced by hyperglycemia-generated oxidative stress. When the glycolytic capacity of  $\beta$ -cells is exceeded by high glucose concentrations, glucose is shunted to other pathways leading to O<sub>2</sub><sup>•-</sup> production (102). In pancreatic  $\beta$ -cells expression of a constitutively active FOXO1 represses glycolysis, increases free fatty acid oxidation, and also reduced insulin secretion (20). Additionally, expression of constitutively active FOXO1 in  $\beta$ -cells of transgenic mice prevents the compensatory proliferation of  $\beta$ -cells that occurs during insulin resistance (60). On the other hand, FOXO1 haploinsufficiency protects against  $\beta$ -cell failure, probably through inhibition of the pancreatic duodenal homeobox-1 gene promoter activity, a gene that is a key regulator of  $\beta$ -cell development (61). In contrast to the above results obtained by introducing constitutive-active alleles of FOXO1, others have shown that FOXO1 can regulate  $\beta$ -cell proliferation and protect against ROS-induced  $\beta$ -cell failure through induction of NeuroD and MafA, two *Insulin2* (*Ins2*) gene transcription factors (19). Such regulation requires acetylation of FOXO1 by p300/CBP to allow the formation a complex with the promyelocytic leukemia protein and the deacetylase SIRT1 (62).

FOXOs' antitumor functions have been discussed above and are mainly mediated through the regulation of genes that control cell cycle arrest and apoptosis. However, with recent work it becomes evident that FOXO may not be a *bona fide* tumor suppressor. For example, the redox-sensitive transcription factors NF- $\kappa$ B and FOXO3a have been described as regulators of matrix metalloproteinase (MMP) expression (110, 114). In response to starvation conditions that previously have been shown to induce oxidative stress, FOXO3a also contributes to increased cell invasion through regulation of the genes encoding MMP-9 and MMP-13 (113). Thus, FOXO transcription factors may contribute to tumor expansion and metastasis. This is interesting since tumor cell metastasis can

be viewed as an integrated escape program that is triggered by changes in the redox state and serves to avoid oxidative stress-mediated damage of cells within the primary tumor. Therefore, oxidative stress-sensitive transcription factors such as FOXO may either induce the stress resistance of cancer cells or induce the migration of cells out of stress areas. Taken together, FOXOs may act as a first line of defense and are tumor suppressors for as long as cells have not become tumorigenic. However, once a tumor is formed many tumor suppressors do not function properly. Similar as known for the multiple roles of transforming growth factor  $\beta$  in tumorigenesis, FOXOs may become pro-tumorigenic or pro-metastatic when reactivated.

FOXO-induced stress resistance could also be important for tumor recurrence. Cancer stem cells (CSC) express stem cell markers, are highly drug resistant, and after radio- or chemotherapy can initiate recurrence. Keeping endogenous and induced oxidative stress at moderate levels mediates drug resistance and allows these cells to survive during treatment (6, 128). For example, human mammary epithelial cancer stem cells contain lower concentrations of ROS, specifically  $O_2^{\bullet-}$ , than normal epithelial cells and the more mature progeny of cancer cells (29). Moreover, these differences in ROS levels are critical for maintaining stem cell function. It is likely that FOXO transcription factors also regulate these important aspects of tumor biology.

#### Other FOXO-regulated stress responses

FOXO signaling is required for the response of hematopoietic stem cells (HSCs) to physiological oxidative stress and the long-term regenerative potential of the hematopoietic stem cell compartment (118). This was implicated for a broad spectrum of tissues [for an additional review see (118)]. FOXO proteins induce stress resistance that led to quiescence and enhanced survival in the HSC compartment (119). Increased expression of FOXO1 was implicated in the regulation of other ROS scavengers such as SOD and catalase to confer resistance to oxidative stress in hematopoietic stem cells (119). Moreover, FOXO-deficient bone marrow showed defective repopulating activity correlating with increased apoptosis of HSC. Further, increases in ROS in FOXO-deficient cells correlated with decreased expression of antioxidant proteins. As an example, the loss of FOXO3a led to defects in HSC and these defects resulted from an accumulation of ROS. FOXO is essential for expression of ataxia telangiectasia mutated, which is critical for oxidative stress-mediated homeostasis of hematopoietic stem cells to preserve the hematopoietic stem cell pool (135).

Another function of ROS-mediated regulation of FOXO at the organismal level is the regulation of the sensitivity of the circadian clock (141). Oxidative stress is one regulator of circadian rhythms. When exposed to oxidative stress, *drosophila* shows attenuated clock gene cycling in peripheral tissues. Flies lacking FOXO expression in the fat body also lost behavioral rhythms driven by the central clock. It was suggested that FOXO has noncell-autonomous effects on central circadian clock function, but may also regulate age-associated rest and activity rhythms (141).

During development of disease cell can experience low oxygen (hypoxic) conditions. Hypoxia induces FOXO transcription *via* direct binding of hypoxia-inducible factor-1 $\alpha$

(HIF-1 $\alpha$ ) to the FOXO3a promoter. Increased FOXO3a expression also resulted in enhanced activity (5). During hypoxia FOXO3a induces expression of CITED2, a transcriptional cofactor that functions as a negative feedback loop to control HIF-1 activity and to inhibit HIF-1-induced apoptosis. Such fine-tuning of HIF-1 activity by FOXO3a contributes to the survival response of normal and cancer cells in response to stress induced by hypoxia (5).

#### Summary

ROS are essential for a large number of cellular processes but are also highly reactive in nature and can result in considerable damage to cellular macromolecules, which contributes to cellular and organismal aging. Moreover, excessive or prolonged ROS formation leads to cellular oxidative stress and was implicated in the onset of a variety of human diseases. Management of ROS levels in cells, whether to prevent potential damage (*i.e.*, in normal cells), or to increase damage (*i.e.*, in cancer cells), can be effective strategies to prevent aging and disease or to cure disease, respectively. Due to their functions as modulators of cellular redox states and decision makers for cellular survival or apoptosis, FOXO transcription factors may be ideal targets for therapeutic approaches aiming to modulate intracellular ROS levels. As an example, nuclear FOXO4 can enhance doxorubicin-mediated cytotoxicity in cancer, and it was suggested that targeting Akt or FOXO4 may provide possibilities in sensitizing cancer cells to cytostatic drugs. This would allow the use of lower drug concentrations to minimize drug-induced adverse effects in patients (79). A potential inducer of FOXO activity is Kaempferol, a flavenoid that increases the lifespan of *C. elegans* probably by translocating DAF-16 to the nucleus (58). Flavonoids are natural dietary components that possess antioxidant activity. On the other hand, many anticancer drugs exuberantly increase intracellular ROS levels to kill cancer cells. It will be interesting to see if the additional inhibition of antioxidant systems will be effective in sensitizing cancer cells to such treatment.

#### Acknowledgments

The author would like to thank Heike Döppler for critical reading of the article. This work was supported by grants from the Mayo Clinic SPORE for Pancreatic Cancer (P50 CA102701), the AACR (08-20-25-STOR), and the NCI (R21 CA135102 and R01 CA140182)—all to P.S.

#### References

1. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B, Wagner T, Vatner SF, and Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. *Circ Res* 100: 1512–1521, 2007.
2. Almeida M, Ambrogini E, Han L, Manolagas SC, and Jilka RL. Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor- $\gamma$  expression, and diminished pro-osteogenic Wnt signaling in the skeleton. *J Biol Chem* 284: 27438–27448, 2009.
- 2a. Ambrogini E, Almeida M, Martin-Millan M, Paik JH, Depinho RA, Han L, Goellner J, Weinstein RS, Jilka RL, O'Brien CA, and Manolagas SC. FoxO-mediated defense

- against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. *Cell Metab* 11: 136–146, 2010.
3. Arner ES and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. *Eur J Biochem* 267: 6102–6109, 2000.
  4. Babior BM. NADPH oxidase: an update. *Blood* 93: 1464–1476, 1999.
  5. Bakker WJ, Harris IS, and Mak TW. FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. *Mol Cell* 28: 941–953, 2007.
  6. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, and Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* 444: 756–760, 2006.
  7. Barthel A, Schmoll D, Kruger KD, Bahrenberg G, Walther R, Roth RA, and Joost HG. Differential regulation of endogenous glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression by the forkhead transcription factor FKHR in H4IIE-hepatoma cells. *Biochem Biophys Res Commun* 285: 897–902, 2001.
  8. Bendayan M and Reddy JK. Immunocytochemical localization of catalase and heat-labile enoyl-CoA hydratase in the livers of normal and peroxisome proliferator-treated rats. *Lab Invest* 47: 364–369, 1982.
  9. Berniakovich I, Trinei M, Stendardo M, Migliaccio E, Minucci S, Bernardi P, Pelicci PG, and Giorgio M. p66Shc-generated oxidative signal promotes fat accumulation. *J Biol Chem* 283: 34283–34293, 2008.
  10. Beutler E. Effect of flavin compounds on glutathione reductase activity: *in vivo* and *in vitro* studies. *J Clin Invest* 48: 1957–1966, 1969.
  11. Bluher M, Kahn BB, and Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. *Science* 299: 572–574, 2003.
  12. Brenkman AB, de Keizer PL, van den Broek NJ, van der Groep P, van Diest PJ, van der Horst A, Smits AM, and Burgering BM. The peptidyl-isomerase Pin1 regulates p27kip1 expression through inhibition of Forkhead box O tumor suppressors. *Cancer Res* 68: 7597–7605, 2008.
  13. Brigelius-Flohe R. Tissue-specific functions of individual glutathione peroxidases. *Free Radic Biol Med* 27: 951–65, 1999.
  14. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, and Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell* 96: 857–868, 1999.
  15. Brunet A, Kanai F, Stehn J, Xu J, Sarbassova D, Frangioni JV, Dalal SN, DeCaprio JA, Greenberg ME, and Yaffe MB. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. *J Cell Biol* 156: 817–828, 2002.
  16. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, and Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHL1 (FOXO3a). *Mol Cell Biol* 21: 952–965, 2001.
  17. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, and Greenberg ME. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. *Science* 303: 2011–2015, 2004.
  18. Burgering BM and Kops GJ. Cell cycle and death control: long live Forkheads. *Trends Biochem Sci* 27: 352–360, 2002.
  19. Buteau J and Accili D. Regulation of pancreatic beta-cell function by the forkhead protein FoxO1. *Diabetes Obes Metab* 9 Suppl 2: 140–146, 2007.
  20. Buteau J, Shlien A, Foisy S, and Accili D. Metabolic diapause in pancreatic beta-cells expressing a gain-of-function mutant of the forkhead protein Foxo1. *J Biol Chem* 282: 287–93, 2007.
  21. Calnan DR and Brunet A. The FoxO code. *Oncogene* 27: 2276–88, 2008.
  22. Carlberg I and Mannervik B. Purification and characterization of the flavoenzyme glutathione reductase from rat liver. *J Biol Chem* 250: 5475–5480, 1975.
  23. Chiribau CB, Cheng L, Cucoranu IC, Yu YS, Clempus RE, and Sorescu D. FOXO3A regulates peroxiredoxin III expression in human cardiac fibroblasts. *J Biol Chem* 283: 8211–8217, 2008.
  24. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, and Sinclair DA. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. *Science* 305: 390–392, 2004.
  25. Copin JC, Gasche Y, and Chan PH. Overexpression of copper/zinc superoxide dismutase does not prevent neonatal lethality in mutant mice that lack manganese superoxide dismutase. *Free Radic Biol Med* 28: 1571–1576, 2000.
  26. Dansen TB, Kops GJ, Denis S, Jelluma N, Wanders RJ, Bos JL, Burgering BM, and Wirtz KW. Regulation of sterol carrier protein gene expression by the forkhead transcription factor FOXO3a. *J Lipid Res* 45: 81–88, 2004.
  27. Dansen TB, Smits LM, van Triest MH, de Keizer PL, van Leenen D, Koerkamp MG, Szypowska A, Meppelink A, Brenkman AB, Yodoi J, Holstege FC, and Burgering BM. Redox-sensitive cysteines bridge p300/CBP-mediated acetylation and FoxO4 activity. *Nat Chem Biol* 5: 664–672, 2009.
  28. de Candia P, Blekhan R, Chabot AE, Oshlack A, and Gilad Y. A combination of genomic approaches reveals the role of FOXO1a in regulating an oxidative stress response pathway. *PLoS One* 3: e1670, 2008.
  29. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, and Clarke MF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. *Nature* 458: 780–783, 2009.
  30. Dijkers PF, Medema RH, Lammers JW, Koenderman L, and Coffey PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. *Curr Biol* 10: 1201–1204, 2000.
  31. Droge W and Kinscherf R. Aberrant insulin receptor signaling and amino acid homeostasis as a major cause of oxidative stress in aging. *Antioxid Redox Signal* 10: 661–678, 2008.
  32. Erol A. Insulin resistance is an evolutionarily conserved physiological mechanism at the cellular level for protection against increased oxidative stress. *Bioessays* 29: 811–818, 2007.
  33. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, and Korswagen HC. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. *Science* 308: 1181–1184, 2005.
  34. Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL, and Burgering BM. FOXO transcription

- factor activation by oxidative stress mediated by the small GTPase Ral and JNK. *EMBO J* 23: 4802–4812, 2004.
35. Finkel T. Radical medicine: treating ageing to cure disease. *Nat Rev Mol Cell Biol* 6: 971–976, 2005.
  36. Finkel T and Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. *Nature* 408: 239–247, 2000.
  37. Flint DH, Tuminello JF, and Emptage MH. The inactivation of Fe-S cluster containing hydro-lyases by superoxide. *J Biol Chem* 268: 22369–22376, 1993.
  38. Frescas D, Valenti L, and Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. *J Biol Chem* 280: 20589–20595, 2005.
  39. Furukawa-Hibi Y, Yoshida-Araki K, Ohta T, Ikeda K, and Motoyama N. FOXO forkhead transcription factors induce G(2)-M checkpoint in response to oxidative stress. *J Biol Chem* 277: 26729–26732, 2002.
  40. Furuyama T, Nakazawa T, Nakano I, and Mori N. Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. *Biochem J* 349: 629–634, 2000.
  41. Giannakou ME, Goss M, Junger MA, Hafen E, Leever SJ, and Partridge L. Long-lived *Drosophila* with overexpressed dFOXO in adult fat body. *Science* 305: 361, 2004.
  42. Glauser DA and Schlegel W. The emerging role of FOXO transcription factors in pancreatic beta cells. *J Endocrinol* 193: 195–207, 2007.
  43. Greer EL and Brunet A. FOXO transcription factors in ageing and cancer. *Acta Physiol (Oxf)* 192: 19–28, 2008.
  44. Harman D. Aging: a theory based on free radical and radiation chemistry. *J Gerontol* 11: 298–300, 1956.
  45. Hashimoto F and Hayashi H. Significance of catalase in peroxisomal fatty acyl-CoA beta-oxidation: NADH oxidation by acetoacetyl-CoA and H<sub>2</sub>O<sub>2</sub>. *J Biochem* 108: 426–431, 1990.
  46. Hofmann B, Hecht HJ, and Flohe L. Peroxiredoxins. *Biol Chem* 383: 347–364, 2002.
  47. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloën A, Even PC, Cervera P, and Le Bouc Y. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. *Nature* 421: 182–187, 2003.
  48. Honda Y and Honda S. The daf-2 gene network for longevity regulates oxidative stress resistance and Mn-superoxide dismutase gene expression in *Caenorhabditis elegans*. *FASEB J* 13: 1385–1393, 1999.
  49. Hoogeboom D and Burgering BM. Should I stay or should I go: beta-catenin decides under stress. *Biochim Biophys Acta* 1796: 63–74, 2009.
  50. Hoogeboom D, Essers MA, Polderman PE, Voets E, Smits LM, and Burgering BM. Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity. *J Biol Chem* 283: 9224–9230, 2008.
  51. Housley MP, Rodgers JT, Udeshi ND, Kelly TJ, Shabano-witz J, Hunt DF, Puigserver P, and Hart GW. O-GlcNAc regulates FoxO activation in response to glucose. *J Biol Chem* 283: 16283–16292, 2008.
  52. Hsu AL, Murphy CT, and Kenyon C. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. *Science* 300: 1142–1145, 2003.
  53. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R, and Hung MC. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. *Cell* 117: 225–237, 2004.
  54. Imai S, Armstrong CM, Kaerberlein M, and Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. *Nature* 403: 795–800, 2000.
  55. Jang SW, Yang SJ, Srinivasan S, and Ye K. Akt phosphorylates Mst1 and prevents its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation. *J Biol Chem* 282: 30836–30844, 2007.
  56. Julien E and Herr W. Proteolytic processing is necessary to separate and ensure proper cell growth and cytokinesis functions of HCF-1. *EMBO J* 22: 2360–2369, 2003.
  57. Junger MA, Rintelen F, Stocker H, Wasserman JD, Vegh M, Radimerski T, Greenberg ME, and Hafen E. The *Drosophila* forkhead transcription factor FOXO mediates the reduction in cell number associated with reduced insulin signaling. *J Biol* 2: 20, 2003.
  58. Kampkotter A, Gombitang Nkwonkam C, Zurawski RF, Timpel C, Chovolou Y, Watjen W, and Kahl R. Effects of the flavonoids kaempferol and fisetin on thermotolerance, oxidative stress and FoxO transcription factor DAF-16 in the model organism *Caenorhabditis elegans*. *Arch Toxicol* 81: 849–858, 2007.
  59. Karger S, Weidinger C, Krause K, Sheu SY, Aigner T, Gimm O, Schmid KW, Dralle H, and Fuhrer D. FOXO3a: a novel player in thyroid carcinogenesis? *Endocr Relat Cancer* 16: 189–199, 2009.
  60. Kitamura T and Ido Kitamura Y. Role of FoxO proteins in pancreatic beta cells. *Endocr J* 54: 507–515, 2007.
  61. Kitamura T, Nakae J, Kitamura Y, Kido Y, Biggs WH 3rd, Wright CV, White MF, Arden KC, and Accili D. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. *J Clin Invest* 110: 1839–1847, 2002.
  62. Kitamura YI, Kitamura T, Kruse JP, Raum JC, Stein R, Gu W, and Accili D. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. *Cell Metab* 2: 153–163, 2005.
  63. Kojima T, Norose T, Tsuchiya K and Sakamoto K. Mouse 3T3-L1 cells acquire resistance against oxidative stress as the adipocytes differentiate via the transcription factor FoxO. *Apoptosis* 15: 83–93, 2010.
  64. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffey PJ, Huang TT, Bos JL, Medema RH, and Burgering BM. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. *Nature* 419: 316–321, 2002.
  65. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffey PJ, Lam EW, and Burgering BM. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. *Mol Cell Biol* 22: 2025–2036, 2002.
  66. Kregel KC and Zhang HJ. An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. *Am J Physiol Regul Integr Comp Physiol* 292: R18–R36, 2007.
  67. Lamitina ST and Strange K. Transcriptional targets of DAF-16 insulin signaling pathway protect *C. elegans* from extreme hypertonic stress. *Am J Physiol Cell Physiol* 288: C467–C474, 2005.
  68. Lee JH, Budanov AV, Park EJ, Birse R, Kim TE, Perkins GA, Ocorr K, Ellisman MH, Bodmer R, Bier E, and Karin M. Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. *Science* 327: 1223–1228, 2010.
  69. Lee KS, Iijima-Ando K, Iijima K, Lee WJ, Lee JH, Yu K, and Lee DS. JNK/FOXO-mediated neuronal expression of fly

- homologue of peroxiredoxin II reduces oxidative stress and extends life span. *J Biol Chem* 284: 29454–29461, 2009.
70. Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villen J, Becker EB, DiBacco S, de la Iglesia N, Gygi S, Blackwell TK, and Bonni A. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. *Cell* 125: 987–1001, 2006.
  71. Li J, Ebata A, Dong Y, Rizki G, Iwata T, and Lee SS. *Caenorhabditis elegans* HCF-1 functions in longevity maintenance as a DAF-16 regulator. *PLoS Biol* 6: e233, 2008.
  72. Li PF, Dietz R, and von Harsdorf R. Superoxide induces apoptosis in cardiomyocytes, but proliferation and expression of transforming growth factor-beta1 in cardiac fibroblasts. *FEBS Lett* 448: 206–210, 1999.
  73. Lin K, Dorman JB, Rodan A, and Kenyon C. daf-16: an HNF-3/forkhead family member that can function to double the life-span of *Caenorhabditis elegans*. *Science* 278: 1319–1322, 1997.
  74. Lin YJ, Seroude L, and Benzer S. Extended life-span and stress resistance in the *Drosophila* mutant methuselah. *Science* 282: 943–946, 1998.
  75. Liou G-Y and Storz P. Reactive oxygen species in cancer. *Free Radic Res* 44: 479–496, 2010.
  76. Litwin JA, Volkl A, Muller-Hocker J, Hashimoto T, and Fahimi HD. Immunocytochemical localization of peroxisomal enzymes in human liver biopsies. *Am J Pathol* 128: 141–150, 1987.
  77. Lu T and Finkel T. Free radicals and senescence. *Exp Cell Res* 314: 1918–22, 2008.
  78. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, and Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. *Cell* 107: 137–148, 2001.
  79. Lupertz R, Chovolou Y, Unfried K, Kampkotter A, Watjen W, and Kahl R. The forkhead transcription factor FOXO4 sensitizes cancer cells to doxorubicin-mediated cytotoxicity. *Carcinogenesis* 29: 2045–2052, 2008.
  80. Maiese K, Chong ZZ, Shang YC, and Hou J. A “FOXO” in sight: targeting Foxo proteins from conception to cancer. *Med Res Rev* 29: 395–418, 2009.
  81. Manolagas SC and Almeida M. Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. *Mol Endocrinol* 21: 2605–2014, 2007.
  82. Martinez-Gac L, Marques M, Garcia Z, Campanero MR, and Carrera AC. Control of cyclin G2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead. *Mol Cell Biol* 24: 2181–2189, 2004.
  83. Medema RH, Kops GJ, Bos JL, and Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. *Nature* 404: 782–787, 2000.
  84. Meng TC, Fukada T, and Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases *in vivo*. *Mol Cell* 9: 387–399, 2002.
  85. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone L, and Pelicci PG. The p66shc adaptor protein controls oxidative stress response and life span in mammals. *Nature* 402: 309–313, 1999.
  86. Minniti AN, Cataldo R, Trigo C, Vasquez L, Mujica P, Leighton F, Inestrosa NC, and Aldunate R. Methionine sulfoxide reductase A expression is regulated by the DAF-16/FOXO pathway in *Caenorhabditis elegans*. *Aging Cell* 8: 690–705, 2009.
  87. Miyaguchi Y, Tsuchiya K, and Sakamoto K. P53 negatively regulates the transcriptional activity of FOXO3a under oxidative stress. *Cell Biol Int* 33: 853–860, 2009.
  88. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, Bultsma Y, McBurney M, and Guarente L. Mammalian SIRT1 represses forkhead transcription factors. *Cell* 116: 551–563, 2004.
  89. Nakae J, Kitamura T, Kitamura Y, Biggs WH 3rd, Arden KC, and Accili D. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. *Dev Cell* 4: 119–129, 2003.
  90. Nakae J, Kitamura T, Silver DL, and Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. *J Clin Invest* 108: 1359–1367, 2001.
  91. Nakashima I, Kato M, Akhand AA, Suzuki H, Takeda K, Hossain K, and Kawamoto Y. Redox-linked signal transduction pathways for protein tyrosine kinase activation. *Antioxid Redox Signal* 4: 517–531, 2002.
  92. Nemoto S, Combs CA, French S, Ahn BH, Fergusson MM, Balaban RS, and Finkel T. The mammalian longevity-associated gene product p66shc regulates mitochondrial metabolism. *J Biol Chem* 281: 10555–10560, 2006.
  93. Nemoto S and Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. *Science* 295: 2450–2452, 2002.
  94. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, Unterman T, and Hay N. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. *Cancer Cell* 14: 458–470, 2008.
  95. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, and Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. *Cell* 102: 849–862, 2000.
  96. Ogg S, Paradis S, Gottlieb S, Patterson GI, Lee L, Tissenbaum HA, and Ruvkun G. The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in *C. elegans*. *Nature* 389: 994–999, 1997.
  97. Oh SW, Mukhopadhyay A, Svrzikapa N, Jiang F, Davis RJ, and Tissenbaum HA. JNK regulates lifespan in *Caenorhabditis elegans* by modulating nuclear translocation of forkhead transcription factor/DAF-16. *Proc Natl Acad Sci USA* 102: 4494–4499, 2005.
  98. Orr WC and Sohal RS. Extension of life-span by overexpression of superoxide dismutase and catalase in *Drosophila melanogaster*. *Science* 263: 1128–1130, 1994.
  99. Parkes TL, Elia AJ, Dickinson D, Hilliker AJ, Phillips JP, and Boulianne GL. Extension of *Drosophila* lifespan by overexpression of human SOD1 in motoneurons. *Nat Genet* 19: 171–174, 1998.
  100. Rached MT, Kode A, Xu L, Yoshikawa Y, Paik JH, Depinho RA, and Kousteni S. FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. *Cell Metab* 11: 147–160.
  101. Rhee SG, Kang SW, Netto LE, Seo MS, and Stadtman ER. A family of novel peroxidases, peroxiredoxins. *Biofactors* 10: 207–209, 1999.
  102. Robertson RP and Harmon JS. Pancreatic islet beta-cell and oxidative stress: the importance of glutathione peroxidase. *FEBS Lett* 581: 3743–3748, 2007.
  103. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, and Puigserver P. Nutrient control of glucose homeostasis

- through a complex of PGC-1alpha and SIRT1. *Nature* 434: 113–118, 2005.
104. Rokudai S, Fujita N, Kitahara O, Nakamura Y, and Tsuruo T. Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis. *Mol Cell Biol* 22: 8695–8708, 2002.
  105. Schon EA. Mitochondrial genetics and disease. *Trends Biochem Sci* 25: 555–560, 2000.
  106. Shimokawa I, Higami Y, Utsuyama M, Tuchiya T, Komatsu T, Chiba T, and Yamaza H. Life span extension by reduction in growth hormone-insulin-like growth factor-1 axis in a transgenic rat model. *Am J Pathol* 160: 2259–2265, 2002.
  107. Smith WW, Norton DD, Gorospe M, Jiang H, Nemoto S, Holbrook NJ, Finkel T, and Kusiak JW. Phosphorylation of p66Shc and forkhead proteins mediates Abeta toxicity. *J Cell Biol* 169: 331–339, 2005.
  108. Speckmann B, Walter PL, Alili L, Reinehr R, Sies H, Klotz LO, and Steinbrenner H. Selenoprotein P expression is controlled through interaction of the coactivator PGC-1alpha with FoxO1a and hepatocyte nuclear factor 4alpha transcription factors. *Hepatology* 48: 1998–2006, 2008.
  109. Srivastava VK, Yasruel Z, and Nalbantoglu J. Impaired medulloblastoma cell survival following activation of the FOXO1 transcription factor. *Int J Oncol* 35: 1045–1051, 2009.
  110. Storz P. Reactive oxygen species in tumor progression. *Front Biosci* 10: 1881–1896, 2005.
  111. Storz P. Reactive oxygen species-mediated mitochondria-to-nucleus signaling: a key to aging and radical-caused diseases. *Sci STKE* 2006: re3, 2006.
  112. Storz P. Mitochondrial ROS—radical detoxification, mediated by protein kinase D. *Trends Cell Biol* 17: 13–18, 2007.
  113. Storz P, Doppler H, Copland JA, Simpson KJ, and Toker A. FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases. *Mol Cell Biol* 29: 4906–4917, 2009.
  114. Storz P, Doppler H, and Toker A. Protein kinase D mediates mitochondria-to-nucleus signaling and detoxification from mitochondrial reactive oxygen species. *Mol Cell Biol* 25: 8520–8530, 2005.
  115. Szatrowski TP and Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. *Cancer Res* 51: 794–798, 1991.
  116. Taub J, Lau JF, Ma C, Hahn JH, Hoque R, Rothblatt J, and Chalfie M. A cytosolic catalase is needed to extend adult lifespan in *C. elegans* daf-C and clk-1 mutants. *Nature* 399: 162–166, 1999.
  117. Tonks NK. Redox redux: revisiting PTPs and the control of cell signaling. *Cell* 121: 667–670, 2005.
  118. Tothova Z and Gilliland DG. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. *Cell Stem Cell* 1: 140–152, 2007.
  119. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, Armstrong SA, Passegue E, DePinho RA, and Gilliland DG. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. *Cell* 128: 325–339, 2007.
  120. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr., DiStefano PS, Chiang LW, and Greenberg ME. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. *Science* 296: 530–534, 2002.
  121. Tran H, Brunet A, Griffith EC, and Greenberg ME. The many forks in FOXO's road. *Sci STKE* 2003: RE5, 2003.
  122. Tullet JM, Hertweck M, An JH, Baker J, Hwang JY, Liu S, Oliveira RP, Baumeister R, and Blackwell TK. Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in *C. elegans*. *Cell* 132: 1025–1038, 2008.
  123. Tyagi S, Chabes AL, Wysocka J, and Herr W. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. *Mol Cell* 27: 107–119, 2007.
  124. Ursini F, Maiorino M, Brigelius-Flohe R, Aumann KD, Roveri A, Schomburg D, and Flohe L. Diversity of glutathione peroxidases. *Methods Enzymol* 252: 38–53, 1995.
  125. van der Heide LP and Smidt MP. Regulation of FoxO activity by CBP/p300-mediated acetylation. *Trends Biochem Sci* 30: 81–86, 2005.
  126. van der Horst A and Burgering BM. Stressing the role of FoxO proteins in lifespan and disease. *Nat Rev Mol Cell Biol* 8: 440–450, 2007.
  127. van der Horst A, Tertoolen LG, de Vries-Smits LM, Frye RA, Medema RH, and Burgering BM. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). *J Biol Chem* 279: 28873–28879, 2004.
  128. Visvader JE and Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nat Rev Cancer* 8: 755–768, 2008.
  129. Walter PL, Steinbrenner H, Barthel A, and Klotz LO. Stimulation of selenoprotein P promoter activity in hepatoma cells by FoxO1a transcription factor. *Biochem Biophys Res Commun* 365: 316–321, 2008.
  130. Wang F, Nguyen M, Qin FX, and Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. *Aging Cell* 6: 505–514, 2007.
  131. Wang MC, Bohmann D, and Jasper H. JNK signaling confers tolerance to oxidative stress and extends lifespan in *Drosophila*. *Dev Cell* 5: 811–816, 2003.
  132. Weindruch R, Naylor PH, Goldstein AL, and Walford RL. Influences of aging and dietary restriction on serum thymosin alpha 1 levels in mice. *J Gerontol* 43: B40–B42, 1988.
  133. Wood ZA, Schroder E, Robin Harris J, and Poole LB. Structure, mechanism and regulation of peroxiredoxins. *Trends Biochem Sci* 28: 32–40, 2003.
  134. Xu D, Rovira II, and Finkel T. Oxidants painting the cysteine chapel: redox regulation of PTPs. *Dev Cell* 2: 251–252, 2002.
  135. Yalcin S, Zhang X, Luciano JP, Mungamuri SK, Marinkovic D, Vercherat C, Sarkar A, Grisotto M, Taneja R, and Ghaffari S. Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells. *J Biol Chem* 283: 25692–705, 2008.
  136. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, and Mayo MW. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. *EMBO J* 23: 2369–2380, 2004.
  137. You H, Jang Y, You-Ten AI, Okada H, Liepa J, Wakeham A, Zaugg K, and Mak TW. p53-dependent inhibition of FKHL1 in response to DNA damage through protein kinase SGK1. *Proc Natl Acad Sci USA* 101: 14057–14062, 2004.
  138. You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M, Villunger A, and Mak TW. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. *J Exp Med* 203: 1657–1663, 2006.

139. Yuan Z, Lehtinen MK, Merlo P, Villen J, Gygi S, and Bonni A. Regulation of neuronal cell death by MST1-FOXO1 signaling. *J Biol Chem* 284: 11285–11292, 2009.
140. Zhang W, Patil S, Chauhan B, Guo S, Powell DR, Le J, Klotsas A, Matika R, Xiao X, Franks R, Heidenreich KA, Sajjan MP, Farese RV, Stolz DB, Tso P, Koo SH, Montminy M, and Unterman TG. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. *J Biol Chem* 281: 10105–10117, 2006.
141. Zheng X, Yang Z, Yue Z, Alvarez JD, and Sehgal A. FOXO and insulin signaling regulate sensitivity of the circadian clock to oxidative stress. *Proc Natl Acad Sci USA* 104: 15899–15904, 2007.

Address correspondence to:  
 Dr. Peter Storz  
 Department for Cancer Biology  
 Mayo Clinic  
 4500 San Pablo Road  
 Jacksonville, FL 32224  
 E-mail: storz.peter@mayo.edu

Date of first submission to ARS Central, June 18, 2010; date of acceptance, July 10, 2010.

#### Abbreviations Used

Abeta = amyloid beta-peptide  
 AD = Alzheimer's disease  
 Bim = Bcl-2-interacting mediator of cell death  
 CBP = cAMP-response element binding protein (CREB)-binding protein  
 FOXO = Forkhead homeobox type O  
 GADD45 $\alpha$  = growth arrest- and DNA damage-inducible gene 45 $\alpha$   
 GSH = glutathione  
 H<sub>2</sub>O<sub>2</sub> = hydrogen peroxide  
 HIF-1 $\alpha$  = hypoxia-inducible factor-1 $\alpha$   
 IGF-1 = insulin-like growth factor-1  
 IKK = inhibitor of nuclear factor- $\kappa$ B kinase  
 JNK = c-Jun-N-terminal kinase  
 MMP = matrix metalloproteinase  
 MST-1 = mammalian ortholog of the Ste20-like protein kinase  
 O<sub>2</sub><sup>•-</sup> = superoxide  
 Prx = peroxiredoxin  
 ROS = reactive oxygen species  
 SGK = serum- and glucocorticoid-inducible kinase  
 SOD = superoxide dismutase  
 Trx = thioredoxin

